Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2020-07-09 Capital/Financing Update
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
THERANEXUS ANNONCE SA POSITION DE TRÉSORERIE AU 30 JUIN 2020 ET LA MISE EN PLACE D'UNE LIGNE DE FINANCEMENT EN FONDS PROPRES
Capital/Financing Update Classification · 98% confidence The document is a press release dated July 9, 2020, announcing two key financial events: the company's proforma cash position as of June 30, 2020, and the establishment of a new equity line financing facility of up to €4.2 million. The content details financing activities, capital structure changes (issuance of warrants/bonds convertible into new shares), and provides a dilution table. This directly aligns with the definition of 'Capital/Financing Update' (CAP), which covers fundraising and capital structure changes. It is not a full Annual Report (10-K), an Earnings Release (ER) which focuses only on results highlights, or a standard Interim Report (IR), as the primary focus is the new financing mechanism.
2020-07-09 French
THERANEXUS OBTIENT UN FINANCEMENT NON DILUTIF DE 3,4 M EUR SOUS FORME DE PRÊT GARANTI (PGE) PAR L'ÉTAT ET FAIT LE POINT SUR SES DEVELOPPEMENTS
Earnings Release Classification · 95% confidence The document is a press release dated June 24, 2020, detailing two main topics: 1) The securing of €3.4M in non-dilutive financing (PGE loan) and the receipt of a €2M R&D tax credit reimbursement, totaling about €6.5M in Q2 2020. 2) Updates on clinical development programs (THN102 and BBDF-101). The text explicitly mentions the company's cash position and future financial reporting dates ('Prochaine publication financière : Jeudi 9 juillet 2020'). This structure—announcing key financial events (financing, cash position) alongside operational/clinical updates—is characteristic of an Earnings Release (ER) or a general corporate update that precedes a formal quarterly report. Since it focuses on key financial highlights (financing secured, cash position update) rather than being a comprehensive quarterly financial statement (which would be an IR), it fits best as an Earnings Release (ER). The document is not a transcript (CT), a formal annual report (10-K), or a specific proxy/governance document. H1 2020
2020-06-24 French
THERANEXUS SECURES EUR 3.4 M LOAN UNDER THE FRENCH STATE GUARANTEE SCHEME (PGE) AND PROVIDES AN UPDATE ON ITS DEVELOPMENTS
Capital/Financing Update Classification · 95% confidence The document is a press release from Theranexus dated June 2020. It primarily announces securing a €3.4 M loan under the French State Guarantee Scheme (PGE) and provides updates on its clinical development programs (THN102 and BBDF-101). It details financing activities (€6.5 M non-dilutive funding in Q2 2020) and provides progress reports on drug candidates, including expected timelines and regulatory interactions (FDA/EMA). This content strongly aligns with announcements related to financing, capital structure changes, and general business/clinical updates, rather than a formal regulatory filing like a 10-K, an earnings release (ER) focused only on results, or a formal dividend notice. The most fitting category for an announcement detailing fundraising success and providing a detailed operational/clinical update is 'Capital/Financing Update' (CAP), as the financing aspect is highlighted prominently in the title and first section. While it contains clinical updates, the primary driver of this specific release seems to be the successful securing of non-dilutive funding.
2020-06-24 English
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly Information Relative to the Total Number of Voting Rights and Shares Comprising the Share Capital) and is dated February 4, 2020, providing data as of January 31, 2020. This explicitly reports on the total number of shares and voting rights, which is a mandatory disclosure in France (under AMF regulations, as cited). This type of periodic disclosure regarding share capital structure and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER) or specific corporate actions (DIV, SHA, POS). It is a specific regulatory disclosure concerning ownership structure. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the closest fit as it deals with changes in ownership structure, although this specific filing is about the total count rather than a specific shareholder crossing a threshold. However, given the nature of mandatory periodic reporting on share capital and voting rights, and the lack of a dedicated code for 'Share Capital/Voting Rights Report', the most appropriate classification based on the provided definitions is either 'RNS' (Regulatory Filings - general fallback) or potentially 'MRQ' if interpreted broadly as related to ownership structure reporting. Since it is a specific, recurring regulatory disclosure about the capital base, and not a general announcement, 'RNS' is the safest fallback if a more specific code isn't available. Let's re-evaluate the options. This is a mandatory disclosure of the total share count and voting rights, often required monthly or quarterly. It is not a Director's Dealing (DIRS), nor a Major Shareholding Notification (MRQ) which usually concerns a specific shareholder crossing a threshold. It is a fundamental regulatory filing. Therefore, the general Regulatory Filings category (RNS) is the most appropriate fit for this specific, non-standardized regulatory report.
2020-02-04 French
DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled "DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS" and provides a table detailing the total outstanding shares and theoretical voting rights as of a specific date (January 31, 2020), referencing French regulatory articles (Commercial Code and AMF General Regulation). This type of periodic disclosure regarding the capital structure and voting power directly relates to shareholder information and voting rights. Among the provided codes, "Declaration of Voting Results & Voting Rights Announcements" (DVA) is the most appropriate fit for a declaration of total voting rights, even though it is not the result of a specific vote, but rather the basis for future votes. It is a formal announcement concerning voting rights.
2020-02-04 English
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 31 DÉCEMBRE 2019
Earnings Release Classification · 99% confidence The document is titled "THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 31 DÉCEMBRE 2019" (Theranexus Publishes its Cash Position as of December 31, 2019). It explicitly states the cash position (€9,452 K€) as of a specific date (Dec 31, 2019) and compares it to the previous quarter (Sept 30, 2019). This content is a summary of financial results for a specific period, which aligns best with an Earnings Release (ER) which typically announces key financial highlights for a period. It is too brief and focused on key figures to be a full Interim Report (IR) or Annual Report (10-K). Since it is an announcement of period-end financial data, ER is the most appropriate classification. Q4 2019
2020-01-27 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.